Abstract: The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis.

Abstract: The present invention provides biomarkers of sensitivity to interferon alfa (IFN-?). These IFN-? sensitivity biomarkers are useful, inter alia, to identify patients who are most likely to benefit from treatment with pharmaceutical compositions of IFN-?, in methods of treating patients having a disease susceptible to treatment with interferon alfa, and in methods for selecting the most appropriate therapy for such patients.

Abstract: A method of treating tuberculosis comprising administering an aerosolized interferon such as interferon ?, interferon ? or interferon ? in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided.

Abstract: The present invention consists of the combination of Interferon alpha and C-Phycocyanin (IFN-?/C-Phyco) for obtaining a pharmaceutical preparation for autoimmune disease, allergy and cancer treatments. The anti-inflammatory, immunomodulator, antioxidant, anti-viral, anti-proliferative and anti-tumoral effects, associated to the regulatory T cell inducer effect demonstrated in this invention is the rationale for the use of the IFN-?/C-Phyco combination in these diseases.

Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zalpha11, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zalpha11, are located on chromosome 16, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

Abstract: The present invention provides novel peptide conjugates. Peptide conjugates of the invention can be used as therapeutic agents. Peptide conjugates invention may also be used to deliver one or more additional active agents. The present invention also provides methods for the treatment of disease by administering to a subject suffering from the disease a composition comprising a peptide conjugate of the invention, optionally.

Abstract: T cell receptors (TCRs) having the property of binding to a murine insulin-derived peptide, LYLVCGERG (SEQ ID NO:62), presented by the murine H-2Kd complex (LYLVCGERG-H-2Kd). The TCRs comprise at least one TCR ? chain variable domain and/or at least one TCR ? chain variable domain and have a KD for the LYLVCGERG-H-2Kd complex of less than or equal to 1 ?M and/or have an off-rate (koff) for the LYLVCGERG-H-2Kd complex of 0.5 S?1 or slower, and use of such TCRs as research tools.

Abstract: The present invention concerns the fields of molecular medicine and targeted delivery of therapeutic agents. More specifically, the present invention relates to the identification of novel peptide sequences that incorporate the amino acids Leu-Pro-Arg (LPR), and particularly D(LPR), that selectively target VEGFR-I and NRP-I expressing cells. Targeted molecules in accor-dance with the invention are useful in the treatment and detection of neovascular or angiogenic VEGF associated disorders, including but not limited to cancer, obesity, diabetes, asthma, arthritis, cirrhosis and ocular diseases.

Abstract: The present invention relates to compositions and methods for fusion protein separation utilizing a peptide linker comprising a novel thrombin cleavage site.

Abstract: A method of reducing formation of non-natural disulfide bonds in a mature IFN-? by adding one or more amino acid residues to its N-terminus cystein. Also disclosed herein is the IFN-? thus modified.

Abstract: Protease resistant modified interferon-beta polypeptides, and pharmaceutical compositions containing such modified interferon-beta polypeptides are provided. The modified interferon-beta polypeptides contain amino acid substitutions that confer increased resistance to proteolysis over unmodified IFN beta cytokine molecules. The present invention provides for pharmaceutical formulations suitable for oral, nasal and pulmonary administration, and the use of such formulations in the treatment of disease.

Abstract: A method of treating tuberculosis comprising administering an aerosolized interferon such as interferon ?, interferon ? or interferon ? in a therapeutically effective amount is provided herein. Further, a method of reducing the infectivity of tuberculosis or reducing the number of infectious organisms present in the lungs of a patient suffering from tuberculosis comprising administering an aerosolized interferon such as interferon ?, interferon ? or interferon ? in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided.

Abstract: The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins.

Abstract: The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA112, CSPG2, TLR2, and CD163.

Abstract: The invention concerns vaccines comprising as an active principle an immunogen which is a cytokinetic factor or a cell regulating factor particularly transcriptional or another type of factor with immunosuppressive/apoptotic/angiogenic properties abnormally released in the extracellular (stromal) environment by cancer or stromal cells of malignant tumors, and a pharmaceutically acceptable carrier for inducing a systemic or mucosal immune response with secretory formation of class IgC or IgA neutralizing antibodies directed against the native factor, or which is derived from such a factor and the use of said immunogen to obtain a medicine for use as anticancer drug.

Abstract: The present invention relates to a human interferon-beta mutein. In particular, the present invention relates to the human interferon-beta mutein having one or two additional sugar chains compared to natural human interferon-beta.

Abstract: Novel compounds of the general formula (I): in which X represents a polymer; Q represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; each of R1 and R2 independently represents a hydrogen atom or a C1-4alkyl group; and either Z1 represents a protein or a peptide linked to CR2 via a nucleophilic moiety, and Z2 represents a molecule linked to CR2 via a nucleophilic moiety, or Z1 and Z2 together represent a single group derived from a protein or peptide linked to CR via two nucleophilic moieties.

Abstract: The invention provides compositions comprising SPARC binding ScFc and its use.

Abstract: The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified amino acid sequences containing artificially created glycosylation site(s), as well as corresponding nucleic acid molecules, vectors and recombinant host cells. The invention also relates to the use of such polypeptides, cells or nucleic acids for curative or preventive treatment of mammalian subjects, including human subjects.

Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16, 25, 49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder characterized by dysregulation of the GH/IGF axis in a mammal, such as a renal disorder.

Abstract: Modified interferon polypeptides with at least one non-naturally-encoded amino acid and uses thereof are provided.

Abstract: The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence.

Abstract: Modified human interferon polypeptides and uses thereof are provided, including PEGylated human interferon polypeptides with one or more non-naturally encoded amino acids.

Abstract: A method for treating an rheumatoid arthritis in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside GM-1 associated activity in an amount effective to treat the disease.

Abstract: The present invention relates to at least one novel cynomolgus IL-13 muteins (Mut-IL-13) proteins, antibodies, including isolated nucleic acids that encode at least one Mut-IL-13 protein or antibody, Mut-IL-13 vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Abstract: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody.

Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Abstract: The present invention relates to a cell line selected from the group consisting of (a) a cell line denominated NM-F9 having the DSMZ accession number DSM ACC2606; (b) a cell line denominated NM-D4 having the DSMZ accession number DSM ACC2605; and subclones of (a) or (b). Additionally, the present invention provides a lysate of the cell lines or a molecule or mixture of molecules obtained from these cell lines as well as dendritic cells loaded with said lysate, co-cultivated or fused with cells from the cell lines, or a molecule or mixture of molecules obtained from these cell lines of the present invention. Moreover compositions, preferably pharmaceutical or vaccine compositions are provided which comprise the cell lines, lysate, molecules, mixture of molecules or dendritic cells of the present invention. In another aspect the present invention relates to methods for producing the aforementioned compositions.

Abstract: Isolated polynucleotides encoding Papio cynocephalus Toll-Like Receptor 3 (Baboon TLR3), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.

Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.

Abstract: Provided are methods of making carrier polypeptide that include incorporating a first unnatural amino acid into a carrier polypeptide variant, incorporating a second unnatural amino acid into a target polypeptide variant, and reacting the first and second unnatural amino acids to produce the conjugate. Conjugates produced using the provided methods are also provided. In addition, orthogonal translation systems in methylotrophic yeast and methods of using these systems to produce carrier and target polypeptide variants comprising unnatural amino acids are provided.

Abstract: The present invention relates to an lnterleukin-21 (IL-21) variant which is capable of increasing the secretion of IgG and/or IgA antibodies in B cells and/or is capable of binding the IL-2 receptor complex and/or the IL-4 receptor complex, comprising stretches of amino acids of lnterleukin-4 (IL-4) or lnterleukin-2 (IL-2) in substitution of amino acids of IL-21. The present invention also relates to a pharmaceutical composition comprising IL-21 and/or an IL-21 variant and at least one compound selected from IgA inducing protein (IGIP), Syntenin-1, Galectin-1 and Galectin-3. The present invention further relates to a pharmaceutical composition for the treatment of a primary humoral immunodeficiency disease comprising IL-21 and/or an IL-21 variant and IL-4 and/or IL-2 and/or IGIP and/or Syntenin-1 and/or Galectin-1 and/or Galectin-3.

Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.

Abstract: The present invention relates to a method for increasing the expression of a protein in cells, preferably in eukaryotic cells, by reducing the number of RNase L cleavage sites in the coding and/or non-coding region of the nucleic acid sequence of said protein. Furthermore, it relates to nucleic acid sequences exhibiting a reduced number of RNase L cleavage sites as well as to the proteins translated from such sequences.

Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.

Abstract: The present invention relates to IL-2 mutants with increased affinity for the IL-2 alpha-receptor subunit (IL-2R?). The invention thus includes IL-2 mutants with improved biological potency. The invention also includes methods for directed evolution of IL-2? using yeast surface display to generate mutants with increased affinity for IL-2R?.

Abstract: The present invention relates to a process for the production of interferon beta, and to an interferon beta composition having a unique glycosylation pattern.

Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.

Abstract: Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus on one subunit of IL-10 with little or no formation of monomeric IL-10. The method also provides a substantially homogenous population of mono-PEG-IL-10.

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders.

Abstract: The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated conditions.

Abstract: The present invention relates to the activation of the CD95L/CD95 system for inducing neuronal differentiation in vitro and in vivo and the use of CD95L compositions to effect differentiation.

Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.

Abstract: The use of certain IL-6-type cytokines for the in vitro maturation of mammalian oocytes is described. The in vitro matured oocytes may be used in in vitro fertilization protocols.

Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.

Abstract: The invention relates to a conjugate that comprises an Apo A molecule or a functionally equivalent variant thereof and a compound of therapeutic interest wherein both components are covalently coupled as well as to the use of said conjugates in therapy for the specific targeting of said compounds to those tissues showing specific binding sites for the ApoA molecule.

Abstract: This invention relates to the use of agents which are capable of the catabolism of components of cartilage extracellular matrix to promote cartilage regeneration within cartilage pathologies and to promote cartilage integration within focal defects.

Abstract: The present invention provides novel artificial oligopeptides capable of binding HLA Class II molecules encoded by several alleles. The oligopeptides include the sequence AX1FVAAX2TLX3AX4A (SEQ ID NO:1), wherein X1 is selected from the group consisting of W, F, Y, H, D, E, N, Q, I and K; X2 is selected from the group consisting of F, N, Y and W; X3 is selected from the group consisting of H and K, and X4 is selected from the group consisting of A, D and E, with the proviso that the oligopeptide sequence is not AKFVAAWTLKAAA. The invention also relates to larger peptides comprising the oligopeptides, polynucleotides encoding the oligopeptides and larger peptides, as well as to compositions comprising the oligopeptides, peptides or polynucleotides. Also disclosed are methods for inducing immune responses.